BACKGROUND: Neurocognitive deficits are among the most debilitating and pervasive symptoms of schizophrenia, and are present also in unaffected first-degree relatives. Also, multiple reports reveal parkisonian motor deficits in untreated subjects with schizophrenia and in first-degree relatives of affected subjects. Yet, the relation between motor and cognitive impairment and its value as a classifier of endophenotypes has not been studied. AIMS: To test the efficacy of midbrain hyperechogenicity (MHE) and parkinsonian motor impairment (PKM) as predictors of neurocognitive impairment in subjects with or at risk for schizophrenia, that could be used to segregate them from first-degree relatives and healthy controls. METHOD: Seventy-six subjects with chronic schizophrenia never exposed to antipsychotic medication, 106 unaffected first-degree relatives, and 62 healthy controls were blindly assessed for cognitive and motor function, and transcranial ultrasound. RESULTS: Executive function, fluid intelligence, motor planning, and hand coordination showed group differences. PKM and MHE were significantly higher in untreated schizophrenia and unaffected relatives. Unaffected relatives showed milder impairment, but were different from controls. CONCLUSIONS: PKM and MHE predict cognitive impairment in neuroleptic-naive patients with schizophrenia and their unaffected first-degree relatives and may be used to segregate them from first-degree relatives and healthy controls.
BACKGROUND:Neurocognitive deficits are among the most debilitating and pervasive symptoms of schizophrenia, and are present also in unaffected first-degree relatives. Also, multiple reports reveal parkisonian motor deficits in untreated subjects with schizophrenia and in first-degree relatives of affected subjects. Yet, the relation between motor and cognitive impairment and its value as a classifier of endophenotypes has not been studied. AIMS: To test the efficacy of midbrain hyperechogenicity (MHE) and parkinsonian motor impairment (PKM) as predictors of neurocognitive impairment in subjects with or at risk for schizophrenia, that could be used to segregate them from first-degree relatives and healthy controls. METHOD: Seventy-six subjects with chronic schizophrenia never exposed to antipsychotic medication, 106 unaffected first-degree relatives, and 62 healthy controls were blindly assessed for cognitive and motor function, and transcranial ultrasound. RESULTS: Executive function, fluid intelligence, motor planning, and hand coordination showed group differences. PKM and MHE were significantly higher in untreated schizophrenia and unaffected relatives. Unaffected relatives showed milder impairment, but were different from controls. CONCLUSIONS: PKM and MHE predict cognitive impairment in neuroleptic-naivepatients with schizophrenia and their unaffected first-degree relatives and may be used to segregate them from first-degree relatives and healthy controls.
Authors: Eduardo Padilla; Juan Molina; Danielle Kamis; Maria Calvo; Lee Stratton; Sergio Strejilevich; Gabriela Gonzalez Aleman; Gonzalo Guerrero; Mercedes Bourdieu; Horacio A Conesa; Javier I Escobar; Gabriel A de Erausquin Journal: Schizophr Res Date: 2014-11-28 Impact factor: 4.939
Authors: Hilary Bertisch; Dawei Li; Matthew J Hoptman; Lynn E Delisi Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2010-06-05 Impact factor: 3.568
Authors: Edson Bor-Seng-Shu; Jose Luiz Pedroso; Andre C Felicio; Daniel Ciampi de Andrade; Manoel Jacobsen Teixeira; Pedro Braga-Neto; Ilza Rosa Batista; Orlando Graziani Povoas Barsottini; Vanderci Borges; Henrique Ballalai Ferraz; Ming Chi Shih; Rodrigo A Bressan; Luiz Augusto Franco de Andrade; Uwe Walter Journal: Parkinsonism Relat Disord Date: 2014-02-06 Impact factor: 4.891
Authors: Paul R A Stokes; Paul Shotbolt; Mitul A Mehta; Eric Turkheimer; Aaf Benecke; Caroline Copeland; Federico E Turkheimer; Anne R Lingford-Hughes; Oliver D Howes Journal: Neuropsychopharmacology Date: 2012-10-24 Impact factor: 7.853
Authors: Juan L Molina; Yash B Joshi; John A Nungaray; Michael L Thomas; Joyce Sprock; Peter E Clayson; Victoria A Sanchez; Mouna Attarha; Bruno Biagianti; Neal R Swerdlow; Gregory A Light Journal: Schizophr Res Date: 2021-09-07 Impact factor: 4.662
Authors: Anne E Willems; Charlotte L Mentzel; Pieter Roberto Bakker; Jim Van Os; Diederik E Tenback; Petra Gelan; Erna Daantjes; Glenn E Matroos; Hans W Hoek; Peter N Van Harten Journal: Schizophr Bull Date: 2022-06-21 Impact factor: 7.348
Authors: Juan L Molina; María Calvó; Eduardo Padilla; Mara Balda; Gabriela González Alemán; Néstor V Florenzano; Gonzalo Guerrero; Danielle Kamis; Beatriz Molina Rangeon; Mercedes Bourdieu; Sergio A Strejilevich; Horacio A Conesa; Javier I Escobar; Igor Zwir; C Robert Cloninger; Gabriel A de Erausquin Journal: NPJ Schizophr Date: 2017-01-11
Authors: Juan L Molina; Michael L Thomas; Yash B Joshi; William C Hochberger; Daisuke Koshiyama; John A Nungaray; Lauren Cardoso; Joyce Sprock; David L Braff; Neal R Swerdlow; Gregory A Light Journal: Transl Psychiatry Date: 2020-11-23 Impact factor: 6.222
Authors: Maija Lindgren; Sebastian Therman; Anna Avellan; Tiina From; Jarmo Hietala; Minna Holm; Tuula Ilonen; Tuula Kieseppä; Heikki Laurikainen; Raimo K R Salokangas; Jaana Suvisaari Journal: Schizophrenia (Heidelb) Date: 2022-08-04
Authors: Lawrence H Yang; Bernalyn Ruiz; Amar D Mandavia; Margaux M Grivel; Liang Y Wong; Michael R Phillips; Matcheri S Keshavan; Huijun Li; Jeffrey A Lieberman; Ezra Susser; Larry J Seidman; William S Stone Journal: Schizophr Res Date: 2020-04-05 Impact factor: 4.939